Evan Thackaberry - Associate Director, Safety Assessment

Evan Thackaberry

Associate Director, Safety Assessment

"I believe that Genentech occupies a unique intersection of scientific excellence and data-driven cross-functional drug development."
7
Years at Genentech
12
Publications
3
Awards & Honors

I joined the Safety Assessment group at Genentech in 2010 and initially focused on developing small molecule and antibody drug conjugate therapies for oncology. I then transitioned to supporting our ophthalmology franchise, and I now serve as the Toxicology Therapeutic Area Leader for ophthalmology. In this capacity, my group focuses on assessing the safety of novel treatments for retinal diseases and works to develop these molecules from target identification through post-marketing. In addition, I am privileged to lead the gRED Ophthalmology Platform Team. This team serves as translational development team for novel ocular delivery technologies and supports the gRED/Roche ophthalmology portfolio as a whole.

Prior to joining Genentech, I served as a discovery and regulatory toxicologist at the Schering-Plough Research Institute, developing early and late stage products across numerous therapeutic areas, and acting as an expert on formulation safety assessment. I received my B.S. in Biochemistry from the University of Vermont, and a Ph.D. in Molecular and Environmental Toxicology from the University of Wisconsin-Madison, where my research focused on the role of the Aryl Hydrocarbon Receptor (AhR) in cardiovascular development. After graduation, I pursued postdoctoral studies focused on cardiovascular developmental toxicology at the University of New Mexico and the Lovelace Respiratory Research Institute.

Featured Publication

Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.

Regul Toxicol Pharmacol. 2017 Jun;86:221-230.

C.L.Z. de Zafra, V.G. Sasseville, S. Matsumoto, C. Freichel, M. Milton, T.K. MacLachlan, C. Farman, I. Raymond, S. Gupta, R. Newton, E.A. Atzpodien, E.A. Thackaberry.